de Wit HM, Vervoort GM, Jansen HJ, et al
Los criterios de no inferioridad describen la existencia del lmite mximo del IC 95% siendo menor a 1,3, mientras que la superioridad estaba definida por un lmite mximo del IC 95% menor a 1, reflejando una reduccin significativa de los eventos estudiados comparados con el grupo control o placebo
The article says GLP-1 medications activate GLP-1 receptors on immune cells, which reduces pro-inflammatory cytokine production, and that chronic inflammation is central to endometriosis pathophysiology
Thats a conversation, not a dead end
3lp), but rather improves liver and cardiovascular health with slightly greater efficacy than GLP-1RGIPR co-agonism (Fig
This huge adherence gap means that real-world effectiveness falls far short of trial efficacy